Why we all need to take steps for Melanoma March
Melanoma March 2022 is aiming to raise $1 million for a world-first clinical trial of a Personalised Immunotherapy Platform which could transform melanoma treatment.
State of the Nation – A Report into Melanoma
A landmark report provides status of melanoma in Australia, and the the roadmap to achieve zero deaths from melanoma this decade.
Neoadjuvant therapy, a breakthrough in Stage III melanoma treatment
In what is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy, a new study has revealed that drug treatment before surgery is effective in preventing deadly spread of the disease.
MIA joins Sydney Health Partners
MIA has joined Sydney Health Partners, with a shared focus on more rapidly translating research evidence into patient benefit.
MIA research wins Cancer Institute of NSW ‘Wildfire Highly Cited Publication’
Cited an incredible 427 times around the world, showing its vital role in improving outcomes for people with advanced melanoma.
Medical Directors receive USYD VC’s Award
The 'Outstanding Research Award' recognises their life-saving discoveries transforming melanoma patient care.
Prof Georgina Long awarded 2021 Ramaciotti Medal
The award recognises her pioneering work in immunotherapy in melanoma, transforming the care of patients worldwide.
MIA researchers on Highly Cited 2021 List
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.
A paradigm shift in melanoma treatment
Drug therapy looks set to become the standard treatment for high-risk early stage melanoma patients.
Prof Georgina Long AO awarded AAHMS Medal
“The future looks bright – I truly believe that we will get to zero deaths from melanoma with the trajectory we’re following.”